ACTU
Actuate Therapeutics Inc
1W: -9.4%
1M: -45.3%
3M: -66.2%
YTD: -61.5%
1Y: -68.4%
$2.35
-0.15 (-6.00%)
After Hours: $2.38 (+0.03, +1.49%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$54.6M
52W Range2.27-11.99
Volume71,416
Avg Volume75,632
Beta0.12
Dividend—
Analyst Ratings
Company Info
CEODaniel Schmitt
Employees10
SectorHealthcare
IndustryBiotechnology
IPO Date2024-08-13
Websiteactuatetherapeutics.com
1751 River Run
Fort Worth, TX 76107
US
Fort Worth, TX 76107
US
817 887 8455
About Actuate Therapeutics Inc
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.
Latest News
Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026
Todd Thomson Sells 280,000 Shares of Actuate Therapeutics (NASDAQ:ACTU) Stock
Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers
Actuate Therapeutics, Inc. (ACTU) Upgraded to Buy: What Does It Mean for the Stock?
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| SCHMITT DANIEL M | M-Exempt | 272,055 | — | 2026-02-13 |
| SCHMITT DANIEL M | F-InKind | 121,874 | $4.33 | 2026-02-13 |
| SCHMITT DANIEL M | M-Exempt | 272,055 | — | 2026-02-13 |
| THOMSON TODD S | S-Sale | 280,000 | $5.80 | 2026-01-05 |
| Bios Equity COF, LP | P-Purchase | 71,428 | $7.00 | 2025-06-27 |